ArticleFrontiers in nutrition2026
Serum 25-hydroxyvitamin D and health-related quality of life in patients with papillary thyroid carcinoma: a prospective cohort study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of papillary thyroid carcinoma (PTC) is rising worldwide. Despite its excellent prognosis, many PTC patients experience impaired Health-Related quality of life (HRQoL). Vitamin D exerts pleiotropic effects on musculoskeletal, immune, and psychological health, but its impact on HRQoL in PTC patients remains unclear. Methods: This prospective cohort study consecutively recruited patients with PTC from January 2024 to August 2025. Baseline serum 25-hydroxyvitamin D concentrations were measured before treatment. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and The Thyroid Cancer-Specific Quality of Life Questionnaire (THYCA-QoL) were applied to assess HRQoL. Associations between serum 25-hydroxyvitamin D and HRQoL domains were examined using rank-transformed general linear models, spearman correlation, multivariable linear regression and binary logistic regression. A nomogram was developed to predict the probability of weight gain in HRQoL domains and evaluated using Harrell's C-index and bootstrap calibration. Results: Among 600 patients, 27.8% had vitamin D deficiency, 69.5% had insufficiency, and 2.7% had sufficiency. Patients with sufficient vitamin D had better physical functioning and lower social functioning scores than those with deficiency or insufficiency ( Conclusion: Suboptimal vitamin D status was common among patients with PTC. Higher vitamin D levels were associated with better physical and role functioning and fewer neuromuscular, psychological, and weight gain symptoms. Assessment of vitamin D status may be considered as part of supportive care when clinically indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.